Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRE | P78334 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242364 | 1.00 | SLC6A1 (0.34) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL2181109 | 1.00 | SLC6A1 (0.34) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL2242371 | 1.00 | SLC6A1 (0.34) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL2686886 | 1.00 | SLC6A1 (0.34) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Carbamic Acid SCHEMBL4773709 | 0.95 | SLC6A1 (0.32) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Carbamic Acid SCHEMBL4774905 | 0.95 | SLC6A1 (0.32) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL16817909 | 0.88 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL16817902 | 0.88 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL2244738 | 0.88 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL16817867 | 0.88 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318940-B2 | Naphthyridin-2 (1 H)-one compounds useful as antibacterials | GLAXO GROUP LIMITED (GB) | 2012-11-27 | — | — | US | disclosed |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-7732461-B2 | (4S)-4-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-3-fluoro-4-hydroxy-4,5-dihydro-7H-pyrrolo[3,2,1-de]-1,5-naphthyridin-7-one, used in the treatment of bacterial infections caused by a wide range of organisms including both gramnegative and grampositive bacteria | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090137568-A1 | Tryclic Nitrogen Containing Compounds and their Use as Antibacterials | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | RIF1, MRPL21, NAT1 | SLC6A1 4874/4885SLC6A11 4883/4885SLC6A13 4880/4885 |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | NAT1, RIF1, MRPL21 | SLC6A1 4866/4885SLC6A11 4876/4885SLC6A13 4875/4885 |
| US-20090137568-A1 | Tryclic Nitrogen Containing Compounds and their Use as Antibacterials | NRDC, NACA, ASNS | SLC6A1 833/4885SLC6A11 721/4885SLC6A13 737/4885 |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | SLC6A1 3713/4885SLC6A11 3508/4885SLC6A13 3871/4885 |
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | SLC6A1 4447/4885SLC6A11 4680/4885SLC6A13 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.